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Abstract
Background. Diffuse low-grade gliomas (DLGGs) are rare and incurable tumors. Whereas maximal safe, functional-
based surgical resection is the first-line treatment, the timing and choice of further treatments (chemotherapy, radi-
ation therapy, or combined treatments) remain controversial.
Methods. An online survey on the management of DLGG patients was sent to 28 expert centers from the European 
Low-Grade Glioma Network (ELGGN) in May 2015. It contained 40 specific questions addressing the modalities of 
use of chemotherapy in these patients.
Results. The survey demonstrated a significant heterogeneity in practice regarding the initial management of 
DLGG patients and the use of chemotherapy. Interestingly, radiation therapy combined with the procarbazine, 
CCNU (lomustine), and vincristine regimen has not imposed itself as the gold-standard treatment after surgery, 
despite the results of the Radiation Therapy Oncology Group 9802 study. Temozolomide is largely used as first-line 
treatment after surgical resection for high-risk DLGG patients, or at progression.
Conclusions. The heterogeneity in the management of patients with DLGG demonstrates that many questions  regarding 
the postoperative strategy and the use of chemotherapy remain unanswered. Our survey reveals a high recruitment po-
tential within the ELGGN for retrospective or prospective studies to generate new data regarding these issues.
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Diffuse low-grade gliomas (DLGGs) (WHO grade  II 
gliomas1) are rare tumors typically affecting young 
patients.2 They are characterized by a continuous growth 
and an almost unavoidable anaplastic transformation.3 
Median overall survival (OS) ranges from 5 to more than 
15  years2,4,5 depending on tumor phenotype, isocitrate 
dehydrogenase (IDH) mutation and 1p19q codeletion, 
tumor size, and spontaneous imaging growth rate.2,6 The 
positive prognostic impact of the extent of resection has 
been demonstrated.5,7 Surgery is considered as the first-
line treatment.8 However, the timing and choice of fur-
ther treatments (chemotherapy, radiation therapy [RT], or 
combined treatments) remain controversial.9–16 To reach 
a treatment decision, several parameters are classically 
taken into account on a case-by-case basis: the presence 
of a residual fluid-attenuated inversion recovery (FLAIR)/
T2 disease,9 known prognostic factors such as older age, 
neurological deficit(s), astrocytic origin, IDH/1p19q status, 
and tumor crossing the midline,17,18 but also rapid imaging 
growth rate2 (increase of the mean tumor diameter [MTD] 
≥8 mm per year before or following surgery6), and patho-
logical neurocognitive status.18
Temozolomide (TMZ),19–22 an oral chemotherapy drug, 
and a multidrug regimen consisting of procarbazine, 
CCNU (lomustine), and vincristine (PCV),4,23,24 have a 
demonstrated efficacy in DLGGs. To date, no trial has 
compared PCV to TMZ as an adjuvant treatment after sur-
gery or at progression in DLGG. The Radiation Therapy 
Oncology Group (RTOG) 9802 trial demonstrated a clear 
survival benefit of PCV following RT in patients with 
“high-risk” DLGG.4 However, this result did not necessarily 
influence practice10,11,16,25 as clinicians still largely propose 
TMZ to patients, in the absence of studies comparing both 
regimens and considering the ease of administration of 
TMZ and the toxicity of PCV.
To date, there are unresolved questions with regards to 
the management of DLGG patients, in particular regarding 
the timing of the introduction of a medical treatment after 
surgery, the position, type, and duration of chemotherapy, 
and whether it should be administered alone or combined 
with RT.
The European Low-Grade Glioma Network (ELGGN) was 
initiated in 2006 and gathers surgical and neuro-oncological 
centers with dedicated teams in charge of DLGG patients. 
An online survey evaluating the current practices in the 
management of DLGG patients was sent to participating 
ELGGN centers in 2015, after the presentation of the results 
of the RTOG 9802 trial at the 2014 American Society of 
Clinical Oncology (ASCO) meeting. The general results of 
this survey have been previously published26 along with 
detailed results regarding its cognitive,27 surgical,28 and im-
aging29 aspects. In this article, we describe the results of the 
survey pertaining to the use of chemotherapy in DLGG.
Material and Methods
The methodology of the survey has been previously 
described.26 In brief, an online survey investigating the 
management of DLGG patients (that is, patients with diffuse 
grade II glioma according to the WHO 2007 classification1) 
was designed by a panel of experts from the ELGGN using 
Google forms and sent to all  participating centers (n = 28) 
in May 2015. It was specified that only one form had to be 
completed for each center and recommended that it should 
be filled out by all physicians involved during a multidis-
ciplinary meeting. The survey contained 69 multiple- and 
single-choice questions divided into 10  sections based 
on the chronological order of events in the management 
of DLGG.
Here we focus on 40 questions specifically addressing 
the use of chemotherapy in DLGG (Table 1). They address 
major issues in the medical management of DLGG 
patients, including 1)  the timing of the introduction of 
chemotherapy in patients with resectable or unresectable 
tumors; 2) the choice of the chemotherapy regimen; 3) the 
value of chemotherapy alone compared to RT or combined 
treatments; and 4) the follow-up on and following chemo-
therapy. Of note, tumors were considered as resectable if 
a residual tumor volume of less than 10 cm3 to 15 cm3 was 
anticipated.
Results
Answers to the survey were obtained from 21/28 centers (re-
sponse rate 75%) distributed across 11 European countries.26 
In these centers, the median number of DLGG patients 
treated with chemotherapy in the “low-grade” period (be-
fore the anaplastic transformation) is 6  patients per year 
per center (range, 0-75) (15 respondents). A  small propor-
tion of these patients are included in clinical trials evaluating 
chemotherapy: 0 in 14/21 centers (66.7%), 1-5 in 4/21 centers 
(19%), 6-10 in 2/21 (9.5%), and >10 patients in 1/21 (4.8%) in 
2014. Interestingly, 10/21 centers (47.6%) have a computerized 
structured database for DLGG patients (updated in 5 centers).
In the following sections, the most relevant results are 
reported. Detailed responses to all questions are provided 
in the Supplementary materials.
Timing and Position of Chemotherapy in the 
Management of DLGG Patients
Initial “wait-and-watch” strategy
In unresectable tumors, an initial “wait-and-watch” 
 strategy is recommended depending on risk factors in 
most centers (14/21, 66.7%). Criteria to discontinue this 
strategy vary by centers: until demonstration of morpho-
logic MRI growth in 8/15 (53.3%), detection of contrast 
enhancement in 6/15 (40.0%), significant spectroscopic 
changes in 3/15 (20.0%), and/or significant perfusion 
changes in 2/15 (13.3%). Chemotherapy (TMZ or PCV) is 
started (after obtaining a histopathological diagnosis by 
biopsy) based on the following criteria in unresectable 
tumors: clinical parameters in 16/20 centers (80.0%), tumor 
volume in 10/20 (50.0%), growth kinetics in 12/20 (60.0%), 
contrast enhancement in 12/20 (60.0%), MRI multimodality 
parameters in 8/20 (40.0%), nuclear imaging parameters in 
1/20 (5.0%), and 1p19q status in 5/20 (25.0%). Of note, the 
duration of the “wait-and-watch” period is ≤6  months in 
13/16 centers (81.2%).
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Table 1 Questions on Chemotherapy in the ELGGN Survey
General questions
Q1 In your center, how many patients with a DLGG receive chemotherapy each year (in the low-grade period)?
Q2 In your center, how many patients with a DLGG have been entered into a therapeutic trial (chemotherapy) in 2014?
Resectable gliomas initial strategy
Q3 Do you recommend an initial “watch and wait” period in resectable DLGG?
Q3bis If yes, how long?
Q3ter On average, this “watch-and-wait” period is about?
Q4 Do you recommend an initial “watch and wait” period in unresectable DLGG?
Q4bis If yes, how long?
Q4ter On average, this “watch and wait” period is about?
Q5 For unresectable DLGG, on which criteria do you start chemotherapy (PCV or TMZ)?
Q6 What do you most commonly recommend as a first line of treatment in unresectable DLGG?
Q7 In some cases, do you prescribe chemotherapy at first line with the objective of optimizing surgical removal (“neoadjuvant 
chemotherapy”)?
Q8 If our group (European DLGG network) proposes a study on “neoadjuvant chemotherapy,” would you participate?
Postoperative strategy
Q9 In case of complete resection of FLAIR, what’s your recommendation?
Q10 In case of subtotal resection of FLAIR (residue less than 10 cc), what’s your recommendation?
Q11 In case of wait and watch, do you evaluate quantitatively the growth rate of the residue?
Q12 Would you say that the selection of adjuvant treatment (either wait and watch, TMZ, PCV, RT alone, concomitant  TMZ and RT, 
or RT plus PCV) is influenced by one of the following proposals?
Choice of chemotherapy (unresectable and resectable DLGGs)
Q13 For DLGG, which chemotherapy do you usually propose as first line?
Q14 Have the results of the Radiation Therapy Oncology Group 9802 study (54 Gy of RT vs the same RT followed by adjuvant  
PCV chemotherapy in high-risk DLGG – median overall survival 7.8 years (RT) to 13.3 years (RT + PCV) – hazard ratio of death  
of 0.59/log rank: P = .002) changed your management of DLGG?
Q15 If yes, have you changed your practice?
Q16 Despite significant toxicity (hematological, general, and long-term toxicities), would you agree to prescribe PCV (in place 
of   TMZ) as first-line treatment if its prolonged response (after the end of treatment) is confirmed (“median duration of 
3.4 years after PCV onset and 2.7 years after the end of PCV” as described by Peyre et al,24 Prolonged response without 
prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas, Neuro Oncol. 2010;12(10):1078–1082)?
Q17 In which cases do you preferentially use PCV?
Follow-up on chemotherapy
Q18 Which maximal number of successive   TMZ cycles do you usually prescribe?
Q19 Do you think it is necessary to systematically evaluate cognition before (during) and after chemotherapy?
Q20 Do you think it is necessary to systematically evaluate quality of life before (during) and after chemotherapy?
Q21 Except clinical trials, do you systematically evaluate patients on quality of life before (during) and after chemotherapy?
Q22 Except clinical trials, do you systematically evaluate patients from a cognitive point of view before (during) and after 
chemotherapy?
Q23 If our group (European DLGG network) reaches an agreement on a minimal standardized cognitive assessment, would you 
agree to follow the recommendations before (during) and at the end of chemotherapy?
Q24 If our group (European DLGG network) reaches an agreement on a minimal quality-of-life assessment, would you agree to  
follow the recommendations before (during) and at the end of chemotherapy?
Q25 If our group (European DLGG network) reaches an agreement on a minimal standardized cognitive assessment, would you 
have the humans resources (neuropsychologists and speech therapists) to systematically evaluate patients before (during) 
and at the end of chemotherapy?
Q26 If our group (European DLGG network) reaches an agreement on a minimal quality-of-life assessment, would you have the 
human resources to systematically evaluate patients before (during) and at the end of chemotherapy?
Q27 How often do you perform MRI evaluation in a patient undergoing chemotherapy (TMZ or PCV)?
Q28 For a given patient on chemotherapy, do you always perform MRI on the same machine?
Q29 For a given patient on chemotherapy, do you always perform a systematic volumetric assessment?
Q30 If yes, which technique do you use?
Q31 If yes, who performs the tumor volume assessment?
















In resectable tumors, an initial “wait-and-watch” strategy 
is always recommended in 3/19 centers (15.8%), never 
 recommended in 10/19 (52.6%), and  recommended de-
pending on risk factors in 6/19 (31.6%). When decided, the 
average duration of the “wait-and-watch” period is short 
(≤6 months) in all responding centers. It is  maintained for 
about 3 months in 8/11 centers (72.7%), until morphologic 
MRI growth in 3/11 (27.3%), detection of contrast enhance-
ment in 4/11 (36.4%), significant spectroscopic changes in 
1/11 (9.1%), and/or significant perfusion changes in 2/11 
(18.2%).
Initial treatment in unresectable tumors
TMZ is commonly proposed as first-line treatment in 15/21 
centers (71.4%), followed by RT in 5/21 (23.8%), RT+PCV in 
2/21 (9.5%), PCV in 1/21 (4.8%), and Stupp regimen in 1/21 
(4.8%). Fourteen of 20 centers (70.0%) sometimes recom-
mend first-line chemotherapy (in a “neoadjuvant” setting) 
to possibly optimize the extent of resection. Eighteen of 
21 (85.7%) would be interested in participating in a clinical 
trial evaluating this strategy.
Postoperative strategy (resectable tumors)
In case of a total resection of the FLAIR tumor volume, 
most centers (16/20, 80.0%) recommend a “wait-and-
watch” strategy. A  systematic and immediate adjuvant 
treatment is never recommended. Molecular tumor 
 markers influence the choice of starting an adjuvant 
treatment in a minority of centers, especially the IDH 
mutation in 2/20 (10.0%), the 1p19q codeletion in 2/20 
(10.0%), and/or the MGMT promoter methylation in 2/20 
(10.0%). In case of a subtotal resection of the tumor (re-
sidual FLAIR volume ≤10 cm3), 11/19 centers (57.9%) rec-
ommend a “wait-and-watch” strategy and 2/19 (10.5%) 
an  immediate treatment. In that case, the decision is 
influenced by the IDH mutation in 4/19 centers (21.1%), 
the 1p19q codeletion in 4/19 (21.1%), and/or the MGMT 
promoter methylation in 2/19 (10.5%).
Position of chemotherapy vs RT and combined 
treatments
The choice of the type of adjuvant treatment is influenced 
by the IDH mutation in 8/20 centers (40.0%), the 1p19q 
codeletion in 10/20 (50.0%), the MGMT promoter methyla-
tion in 3/20 (15.0%), and by none of these parameters in 
8/20 centers (40.0%).
The results of the RTOG 9802 clinical trial (median OS 
13.3 years in patients treated with RT-PCV vs 7.8 years in 
patients treated with RT)4 modified the management of 
DLGG patients in 7/20 centers (35.0%). This resulted in a 
change of practices in high-risk patients in only 8/8 centers.
Choice of chemotherapy regimen
TMZ is preferred over PCV as first-line chemotherapy 
in 16/21 centers (76.2%). Ten of 20 centers (50.0%) would 
agree to prescribe first-line PCV if the prolonged responses 
after the end of PCV initially reported by Peyre et  al are 
confirmed.24 PCV is preferentially used in case of 1p19q 
codeletion in 8/21 centers (38.1%), clinical progression 
(headache, neurological deficit, intractable epilepsy) in 5 
(23.8%), contrast enhancement in 4 (19.0%), large tumor 
volume in 3 (14.3%), growth kinetics >6 mm per year in 3 
(14.3%), young patients in 2 (9.5%), and/or based on nu-
clear imaging in 1 (4.8%). PCV is never used as first-line 
treatment in 6 centers (28.6%).
Follow-up and response assessment of 
chemotherapy
The maximal number of successive TMZ cycles  prescribed 
is 12 in 9/21 centers (42.9%), 18 in 3/21 (14.3%), 24 in 4/21 
(19.0%), and unlimited in 5/21 (23.8%). Next to new contrast 
enhancement, which defines transformation to a higher 
grade, the following criteria are used to decide the discon-
tinuation of    TMZ because of progression: FLAIR volume in-
crease >25% compared to baseline imaging in 15/21 centers 
(71.4%), FLAIR volume increase >25% between 2 successive 
Table 1 Continued
Q32 It is always the same person who performs the tumor volume assessment?
Q33 For stopping chemotherapy because of a progression without anaplastic transformation, which radiological criteria do you 
consider relevant?
Q34 For response assessment, do you use RANO criteria?
Q35 In your opinion, is the volumetric assessment through the 3 diameters method reproducible?
Q36 In your opinion, is the volumetric assessment through segmentation reproducible?
Q37 In your opinion, is the volumetric assessment essential for the monitoring of an DLGG patient on chemotherapy?
Q38 In your opinion, is the rCBV essential for the monitoring of an DLGG patient on chemotherapy?
Q39 In your opinion, is the spectroscopy essential for the monitoring of an DLGG patient on chemotherapy?
Q40 For multitreated and reshaped lesions, with difficulties of volumetric quantification, which parameter(s) among the following 
may modify your strategy?
Abbreviations: DLGG, diffuse low-grade glioma; ELGGN, European Low-Grade Glioma Network; FLAIR, fluid-attenuated inversion recovery; PCV, 
procarbazine, CCNU (lomustine) and vincristine; RANO, Response Assessment in Neuro-Oncology; rCBV, relative cerebral blood volume; RT, radio-
therapy; TMZ, temozolomide.
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MRIs in 8/21 (38.1%), perfusion imaging (relative cerebral 
blood volume [rCBV] increase) in 3/21 (14.3%), and/or sig-
nificant spectroscopy changes in 5/21 (23.8%).
A systematic evaluation of the neurocognitive function 
is considered necessary to evaluate DLGG patients during 
and after chemotherapy in 15/21 centers (75.0%). In daily 
practice (clinical trials excluded), only 3/21 centers (14.3%) 
systematically perform such evaluation. Most centers 
(15/18) would agree to follow ELGGN recommendations 
if an agreement on a minimal standardized cognitive 
assessment was reached. Many of them (13/21) would 
have the human resources available to do so.
In 19/21 centers (90.5%), a systematic evaluation of 
 quality of life (QOL) is considered necessary during and 
after chemotherapy, but is performed systematically in 
only 8/21 centers (38.1%) in daily practice. Most centers 
(20/21) would agree to follow ELGGN recommendations if 
an agreement on a minimal QOL assessment was reached 
and would have the resources to do so (17/21).
Regarding imaging evaluation of DLGG patients 
 receiving chemotherapy, 95.3% of centers perform an MRI 
every 2 or 3 cycles (20/21 centers). Volumetric assessment 
of the FLAIR tumor volume is considered as essential in 
16/19 centers (80.0%). It is systematically performed in 
10/21 centers (47.6%), based on a segmentation technique 
in most cases (12/14), and always by the same person in 
13/16 centers (81.3%). Volumetric assessment through 
segmentation is considered reproducible in 15/20 centers 
(75.0%) while it is considered reproducible in only 4/20 
centers (20.0%) when performed using the 3 diameters 
method.
Twelve of 21 centers (57.1%) use the Response 
Assessment in Neuro-Oncology (RANO) criteria for re-
sponse assessment in DLGG patients. rCBV and spectro-
scopic parameters (choline/N-acetyl-aspartate index) are 
considered essential in the monitoring of DLGG patients 
receiving chemotherapy in 19% (4/21) and 25% (5/20) 
of centers, respectively. For multitreated and reshaped 
tumors, with difficulties for the volumetric measurements, 
the treatment strategy is modified by contrast enhance-
ment in 19/21 centers (90.5%), rCBV in 15/21 (71.4%), and 
spectroscopic changes in 6/21 (28.6%).
Discussion
This study describes the daily clinical practices regarding 
the use of chemotherapy in DLGG patients among 
specialized European centers. The high participation rate 
(75%) shows that the ELGGN centers are highly involved in 
the management of these patients and in the network. For 
comparison, a response rate of only 30.2% was achieved 
in a survey sent to neurosurgeons, neuro-oncologists, and 
radiation therapists from Australia and New Zealand.11 One 
limitation, however, is that despite our recommendations, 
we cannot be certain that a multidisciplinary consensus 
was reached for the responses.
Despite the low incidence of DLGG, the recruitment of 
patients receiving chemotherapy at the low-grade stage 
of the disease is significant among participating  centers 
(about 200 patients per year total). This recruitment 
would allow for large retrospective or prospective  studies 
within the ELGGN. To date, despite the specialization of 
the ELGGN teams in the management of DLGG, only 
a few patients are included in clinical trials evaluating 
 chemotherapy,  probably because of the paucity of trials 
and because early RT is often used as a comparative arm 
or in association with chemotherapy in these trials.
Timing and Position of Chemotherapy in the 
Management of DLGG Patients
Initial strategy
Overall, we found that, whatever the tumor resectability, 
treatment is usually started shortly after the tumor diag-
nosis. Indeed, it is our opinion that patients should receive 
treatment(s) as soon as a volumetric tumor growth has been 
demonstrated, to reduce the tumor volume and the risk of 
anaplastic transformation.5 Treatment is started earlier in re-
sectable compared with unresectable tumors: no “wait-and-
watch” period in 52.6% for resectable tumors, compared 
with 19.0% for unresectable tumors. When decided, the 
“wait-and-watch” period is also shorter for resectable tumors 
(always ≤6 months vs 6-12 months in 18.8% of centers for 
unresectable tumors). Surprisingly, the treatment is started 
only when contrast enhancement appears in a significant 
proportion of centers, whatever the resectability of the tumor 
(36% and 40% of centers for resectable and unresectable 
tumors, respectively). However, this result could be due 
to a misinterpretation of the question (when contrast en-
hancement appears there is an undisputable indication for 
treatment). In  unresectable tumors, the decision to start a 
“medical” treatment is based on various factors including 
clinical, imaging (tumor volume, growth rate, contrast en-
hancement, MRI multimodality parameters, nuclear im-
aging), and biological  parameters (1p19q codeletion). In 60% 
of centers, this decision is based on the detection of contrast 
enhancement. This could mean that in a proportion of centers, 
the anaplastic transformation of the disease (as reflected by 
the occurrence of contrast enhancement) is a strong signal of 
the necessity for a treatment. Again, this result could also be 
due to a misinterpretation of the question.
Interestingly, a large proportion of centers do not pro-
pose a “wait-and-watch” period, whatever the tumor 
resectability, despite the demonstrated prognostic value 
of the spontaneous growth rate.6 This might be partly be-
cause a number of centers do not have a reliable method 
for accurately calculating the spontaneous growth rate.
In patients with an unresectable DLGG, first-line chemo-
therapy to optimize the extent of resection can be proposed 
by 70% of the centers, many of which would be interested 
in participating in a retrospective or prospective study. 
This strategy has been investigated in several single-center 
studies30–32 and seems to constitute a promising option. 
It needs to be further evaluated in larger studies and 
validated in prospective trials, possibly within the ELGGN.
Postoperative strategy
A postoperative “wait-and-watch” period is largely 
preferred by the responding centers following a total (80% 
















of centers) or subtotal resection (57.9% of centers) of the 
FLAIR volume, despite the recent results of the RTOG 9802 
study that promote postoperative RT and chemotherapy 
in high-risk DLGG patients (of note, the questionnaires 
were sent after the presentation of the results at the 2014 
ASCO meeting but before the 2016 publication of Buckner 
et  al4; it remains unknown whether the full publication 
might have changed the responses). After subtotal re-
section, the decision of adjuvant treatment is influenced 
by molecular data in a minority of centers. Indeed, the 
use of molecular parameters alone to predict outcome 
and determine treatment strategies is questionable. As 
an example, IDH wild-type DLGG, classically associated 
with a poor prognosis, can have prolonged survival after 
surgery.33 Therefore, we believe that IDH status should 
not be considered alone to make treatment decisions 
(including adjuvant treatment after surgery), but in asso-
ciation with other parameters including not only tumor 
biology (including but not limited to molecular features) 
but also clinical (age, neurological, and neurocognitive 
status), imaging parameters (spontaneous growth rate, 
volume of the FLAIR residue,9 perfusion, spectroscopy, 
and nuclear imaging parameters), and extent of resection 
(MRI-quantified total resection and supratotal resection). 
This raises the question of the definition of “high-risk” 
patients who should receive immediate adjuvant 
treatment after surgery. In the past, several prognostic 
scores have been designed17,18; however, none of them 
has included the spontaneous growth rate,6 tumor mo-
lecular biology, treatment modalities (including the ex-
tent of resection), or functional parameters. The planned 
European Organization for Research and Treatment of 
Cancer (EORTC) I-WOT study comparing immediate ad-
juvant treatment (“treat”) to follow-up (“wait”) following 
resection in IDH-mutant, 1p19q-intact lower-grade glioma 
patients will provide new data regarding this question.
Place of Chemotherapy vs RT and Combined 
Treatments
RT is an effective treatment and was long considered as 
the standard treatment following surgery in DLGG.34 
However, the EORTC 22845 phase III trial found that early 
RT had no impact on OS compared to late RT, despite an 
increased progression-free survival (PFS).35 Moreover, it is 
 associated with early and late cognitive toxicity.36,37
Efficacy of chemotherapy alone (TMZ or PCV) in DLGG 
patients has been reported in several studies.19–24 It was 
recently confirmed by 2  large prospective studies,4,38 
including the long-term results of the RTOG 9802 
phase III trial comparing RT alone to RT-PCV in high-risk 
DLGG patients.4 The EORTC 22033 trial showed no sig-
nificant difference in PFS in patients receiving dose-
dense TMZ or RT as initial adjuvant treatment.38 Of note, 
high-risk IDH-mutant non-codeleted DLGG individuals 
had a shorter PFS in the TMZ arm compared with the 
RT-alone arm in this study; however, the groups are small 
and data on OS are not yet available, precluding any de-
finitive conclusion.
Owing to the demonstrated efficacy of chemotherapy in 
DLGG, the absence of benefit on OS of early (vs late) RT, 
and the evidence of decreased neurocognitive  functioning 
following RT, many physicians choose to delay RT until 
a later stage of the disease and to prefer chemotherapy 
alone as initial treatment. In our survey, we found that 
chemotherapy alone is still chosen by a number of centers 
either right after surgery in an “adjuvant” setting or later at 
progression.
This strategy is being currently challenged by the recent 
results of the RTOG 9802 trial, which evaluated multimodal 
treatment combining RT and chemotherapy.4 This study 
demonstrated a clear survival benefit of adding chemo-
therapy to RT in “high-risk” patients (median OS 13.3 vs 
7.8  years in patients treated with RT alone, hazard ratio 
[HR] of death 0.59). However, several concerns have been 
highlighted, precluding any generalization of this strategy 
and explaining why the management of patients remains 
heterogeneous from center to center.11 First, the popula-
tion of patients included in this trial might not be a good 
representation of a “true” DLGG population. Indeed, 38% 
of patients presented with contrast enhancement on im-
aging (vs 15% to 20% in previous studies on DLGG2). 
Moreover, only a moderate proportion of patients (61% 
to 64%) had an IDH-mutant tumor, a quite surprising fact 
for a DLGG series. Second, the survival analyses did not 
take into account the extent of resection, which has been 
shown to be a positive prognostic factor.5,7 Importantly, 
only a few patients underwent gross total resection (9% 
in the RT arm and 11% in the combined treatment arm). 
Third, it would have been interesting to compare the 
results of RT and combined RT-PCV arms to that of PCV 
alone. Finally, the lack of comparative QOL data is a main 
issue, as well as the insufficiency of the neurocognitive 
assessment, which included only a MMSE with no 
prolonged follow-up.36 Of note, the interim results from 
the CATNON trial (EORTC 26053-22054) of RT with concur-
rent and adjuvant TMZ for 1p19q-intact anaplastic gliomas 
suggest an increased survival for patients receiving adju-
vant TMZ.39 However, extrapolating this result to low-grade 
astrocytomas is delicate.
A recent population-based study from the retrospective 
United States (US) National Cancer Database has provided 
interesting data regarding the use of the association of RT and 
chemotherapy.40 It included 1054 patients with “high-risk” 
DLGG (as defined by the RTOG 9802 trial) receiving medical 
treatment within the first 6 months after diagnosis. A total of 
496 patients (47.1%) received chemotherapy alone (one drug 
in 89.3% of cases, most likely TMZ) and 558 (52.9%) under-
went radiochemotherapy (with one drug in 92.5% of cases, 
most likely TMZ). The group of combined treatment was not 
associated with improved OS (P = .125). However, this study 
has some limitations. First, the duration of the follow-up is 
short (median 4.6  years) while the RTOG 9802 study (me-
dian follow-up 11.9 years) demonstrated a separation of the 
OS curves (RT alone vs RT-PCV) after 4  years.4 Secondly, 
the chemotherapy group is favored with 22.8% of patients 
having a 1p19q-codeleted tumor compared with 7.5% in 
the radiochemotherapy group (P  <  .001). Finally, the ana-
lysis suffers from  missing data regarding the IDH mutation 
(missing in all cases), the 1p19q-codeletion status (missing 
in 78% of cases), the extent of resection (missing in 53% of 
cases), or the tumor volume (missing in 37% of cases).
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In another study from the US National Cancer Database, 
1466 DLGG patients treated with RT alone were compared 
with 787 patients treated with chemotherapy alone as first-
line treatment after surgery.41 In the multivariate analysis 
(including patient’s age and extent of resection), chemo-
therapy was the only factor associated with improved sur-
vival (HR: 0.405, P <  .001). Again, this study suffers from 
limitations, in particular the fact that molecular biology 
parameters could not be considered in the multivariate 
analysis because of missing data (1p19q status unknown 
in 83% of cases). This limitation is all the more important 
given that, among patients with a known 1p19q status, 
66.8% in the chemotherapy group had a codeleted tumor 
compared with 33.82% in the RT group.
In our survey, the choice of the adjuvant treatment (chemo-
therapy vs RT vs combined treatment) is influenced by the 
IDH status in 40.0% of centers, the 1p19q status in 50.0%, 
and none of these parameters in 40%. Indeed, a positive 
effect of chemotherapy has been shown whatever the mo-
lecular status, including in DLGG patients with unfavorable 
molecular features.22,31,32 In the study by Ricard et al, 50% of 
38 patients with a 1p19q–non-codeleted DLGG had a minor 
or partial response under TMZ, and 39.5% showed a stable 
disease.22 In another study of patients treated with TMZ in a 
“neoadjuvant” setting, the IDH and 1p19q status had no sig-
nificant impact on the velocity of the MTD decrease.31
In summary, the decision regarding oncological treatments 
all along the DLGG evolution should rely, on a case-by-
case basis, on the integration of many factors including 
age,  cognitive and epileptic status, tumor growth kinetics, 
extent of resection, molecular markers, and comparison 
between survival and expected toxicity.13 In this context, well-
conducted, prospective population-based studies at the inter-
national level are of the upmost importance to better evaluate 
treatment strategies according to these multiple factors.
Choice of Chemotherapy Regimen
Several chemotherapy regimens have shown efficacy in 
DLGG. An efficacy of TMZ in newly diagnosed or recur-
rent DLGGs has been demonstrated in multiple phase  II 
 studies,19–21,42 including studies with volumetric assessment 
of the MTD.22,31 In a series of 39 DLGG patients receiving 
TMZ, 92% experienced an initial decrease of the MTD,22 
with a longer duration of response for patients with a 1p19q-
codeleted tumor, confirming previous data.21 Of note, in a re-
cent study of 120 IDH-mutant DLGGs included in the EORTC 
22033 trial, a high MGMT methylation score was predictive 
of a benefit from TMZ treatment, regardless of 1p19q status.43
Objective responses rates have been shown with PCV in 
multiple single-arm studies in DLGG,23,24 including studies 
with volumetric assessment.24,44 The impact of PCV on sur-
vival has been recently confirmed by the RTOG 9802 trial.4
Although they have not been compared prospectively in 
DLGG, TMZ and PCV appear to be associated with different 
patterns of response. The time to maximum tumor volume 
reduction is shorter with TMZ: median time to maximum 
response 12 months (range, 3-30 months) with TMZ,21 me-
dian time to maximal MTD decrease 40.8  months with 
PCV.24 The duration of response is longer with PCV: median 
duration of MTD decrease 40.8 months with PCV,24 median 
PFS 28 months with TMZ.21 Data regarding this question 
of TMZ vs PCV come from studies in anaplastic gliomas. 
In the German Neuro-Oncology Working Group (NOA)-
04 trial, patients enrolled in the chemotherapy arm were 
randomized to receive either TMZ or PCV. No difference in 
outcome has been demonstrated so far.45 In a randomized, 
clinical trial comparing PCV vs 2 different schedules of TMZ 
in high-grade glioma patients at first recurrence, there 
was no survival benefit of PCV.46 Of note, the ongoing 
CODEL trial (NCT00887146) evaluating RT with TMZ or PCV 
includes patients with anaplastic glioma and patients with 
“high-risk” DLGG, and will provide further data.
Our survey shows that for most centers within the 
ELGGN, TMZ remains the reference treatment in DLGG, as 
there are currently not enough data supporting the use of 
PCV over TMZ, and considering the ease of administration 
of TMZ and the feared toxicity of PCV. PCV is used as the 
first-line treatment in a wide range of situations. The dis-
parity of responses shows that there is no consensus.
Follow-up and Response Assessment of 
Chemotherapy
Evaluation of the imaging response
Imaging monitoring seems fairly codified in DLGG 
patients treated with chemotherapy (MRI every 2 or 3 
cycles). The RANO group recently proposed new criteria 
to define tumor response in DLGG.47 These criteria are 
not  systematically used within the responding ELGGN 
centers (57% of centers). Indeed, while the effort to stand-
ardize tumor response and to incorporate FLAIR signal 
changes and clinical status (including steroids use) to the 
response criteria must be emphasized, the lack of 3-dimen-
sional volumetric assessment of FLAIR signal changes is a 
major limitation, in particular for the evaluation of residual 
reshaped tumors after surgery.48–50 Our survey shows that 
the volumetric assessment of FLAIR volume is considered 
essential in most ELGGN centers (80%). Indeed, the value 
of 3-dimensional volumetric assessment of FLAIR signal 
changes has been well described.22,24,49–51 When segmenta-
tion is used, it is considered reproducible in most centers. 
It is indeed reproducible and independent of the physician, 
the medical specialty, or years of experience.52 Moreover, 
autopsy studies have demonstrated a good correlation 
between the measured volume using segmentation and 
the real volume.53 Despite these considerations, a volu-
metric assessment of the FLAIR volume in DLGG patients 
receiving chemotherapy is systematically performed in only 
half of the responding centers, probably linked to the lack of 
available and appropriate software and to the fact that the 
manual segmentation technique is time consuming. Semi-
automated segmentation techniques are being developed 
and will be of great assistance. In our opinion, modified 
RANO criteria including a volumetric assessment of the 
FLAIR volume should be evaluated further.
Evaluation of QOL and neurocognitive functioning on 
chemotherapy
Data regarding the impact of chemotherapy on QOL and 
neurocognitive functioning in DLGG are scarce. A  few 
studies seem to indicate no alteration of QOL in DLGG 
















patients receiving TMZ19,30,54–56 and a reversible alteration of 
QOL during the PCV regimen and shortly after PCV. Only 
a few studies have performed an extensive and longitu-
dinal assessment of cognitive function on chemotherapy.30 
Yet, it has been established that neurocognitive deficits 
lead to lower QOL in DLGG patients.57 The neurocognitive 
assessment was limited to the restrictive MMSE evaluation 
in several recent clinical trials.55,58 Moreover, the follow-up 
period is often short.30,55 A baseline evaluation is not always 
included, altering the interpretation of the results as several 
variables affect neurocognitive functioning: the tumor itself, 
epilepsy and antiepileptic drugs, surgery, the premorbid 
level of cognition, and psychopathological affects.34,59
The impact of TMZ followed by surgery on cognition and 
QOL was evaluated in 10 patients with an unresectable 
DLGG, in a neoadjuvant setting or at recurrence after par-
tial surgery.30 After completing the whole protocol (TMZ and 
surgery), 3 patients had no cognitive deficit while 7 patients 
had only a slight deficit (verbal episodic memory and ex-
ecutive function mostly). QOL was preserved. In the EORTC 
22033-26033 phase III trial (first-line TMZ vs RT in high-risk 
DLGG patients), no difference in MMSE score was found, 
but the follow-up was short (36  months).55 In the RTOG 
9802 trial, the adjunction of PCV to RT did not affect the 
proportion of patients with an MMSE score decline (max-
imum follow-up 5 years).4 Other data regarding the cogni-
tive impact of chemotherapy are available from  studies in 
anaplastic gliomas, but the extrapolation of results to DLGG 
patients seems problematic because anaplastic gliomas are 
more  aggressive tumors frequently associated with more 
severe deficits, and patients are often treated with RT along 
with chemotherapy and less frequently with TMZ.60
In our survey, most centers consider the evaluation of 
QOL and neurocognitive functioning in patients  receiving 
chemotherapy necessary and would agree to follow 
ELGGN recommendations if an agreement on a minimal 
standardized assessment (ie, as proposed by Klein59) was 
reached. Resources seem to be more or less sufficient in 
participating centers; however, it might not be the case in 
all neuro-oncological centers.
In summary, data regarding the impact of TMZ on QOL and 
neurocognitive functioning in DLGG patients are scarce. It 
is important, however, to accurately evaluate these aspects 
in consideration of young age, generally preserved QOL at 
diagnosis, possible implications of the disease on the pro-
fessional (DLGG patients are often still active), social, and fa-
milial domains, and relatively long survival of these patients. 
In the absence of a curative treatment for DLGG, preserving 
patients’ QOL is indeed a major goal.
Summary
At the individual level, several criteria must be considered 
when evaluating DLGG patients treated with chemo-
therapy to determine the best individualized strategy. These 
criteria must also be taken into account in clinical trials. 
In patients treated with chemotherapy (in particular with 
TMZ), they must be considered altogether when deciding 
the duration of treatment. Indeed, while the PCV regimen 
is usually administered for 4 to 6 cycles, the question of 
the duration of treatment needs to be clarified in DLGG 
patients treated with TMZ. It is not clear yet if, like PCV, TMZ 
should be discontinued after a predetermined number of 
cycles or if it should be continued as long as the tumor 
 volume decreases, considering that the treatment can be 
continued if tolerance is good (including regarding QOL and 
neurocognitive functioning) and the volumetric response 
clearly documented.
Conclusion
The survey demonstrated a significant heterogeneity in 
practices among expert centers within the ELGGN regarding 
the initial management of DLGG patients and the use of 
chemotherapy. Combined RT and chemotherapy has not 
imposed itself as the gold-standard treatment after surgery, 
despite the recent results of the RTOG 9802 study.4 This is 
certainly linked in part to the fact that patients included in this 
trial were highly selected and represent only a subpopulation 
of DLGG. TMZ is largely used as first-line treatment after 
surgical resection for “high-risk” DLGG patients, or at pro-
gression. Many questions regarding the postsurgical man-
agement of DLGG patients and the use of chemotherapy 
remain unanswered. Our survey reveals a high recruitment 
potential within the ELGGN for retrospective or prospective 
studies to generate some new data regarding these issues. 
For example, the ELGGN will aim in the near future at 
assessing the survival and functional benefit of first-line PCV 
vs TMZ, as well as of upfront RT-PCV compared with a more 
“sequential” strategy delaying RT and PCV.
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